![Ashish M. Kamat, MD, MBBS on X: "Impact Factors for 2023 are out! Top Ten for #urology collated by @KariTikkinen Congratulations to @EUplatinum @EurUrolOncol @NatRevUrol @EurUrolFocus @JUrology @BJUIjournal https://t.co/aoNwgRRlD3" / X Ashish M. Kamat, MD, MBBS on X: "Impact Factors for 2023 are out! Top Ten for #urology collated by @KariTikkinen Congratulations to @EUplatinum @EurUrolOncol @NatRevUrol @EurUrolFocus @JUrology @BJUIjournal https://t.co/aoNwgRRlD3" / X](https://pbs.twimg.com/media/FzuydDJX0AgkchJ.jpg:large)
Ashish M. Kamat, MD, MBBS on X: "Impact Factors for 2023 are out! Top Ten for #urology collated by @KariTikkinen Congratulations to @EUplatinum @EurUrolOncol @NatRevUrol @EurUrolFocus @JUrology @BJUIjournal https://t.co/aoNwgRRlD3" / X
![ASCO GU 2023: PARP Inhibitors in Metastatic Castration Resistant Prostate Cancer (mCRPC): TRITON3 and TALAPRO-2 ASCO GU 2023: PARP Inhibitors in Metastatic Castration Resistant Prostate Cancer (mCRPC): TRITON3 and TALAPRO-2](https://www.urotoday.com/images/com-doc-importer/103-asco-gu-2023/asco-gu-2023-discussion-of-triton-3-and-talapro-2/image-0.jpg)
ASCO GU 2023: PARP Inhibitors in Metastatic Castration Resistant Prostate Cancer (mCRPC): TRITON3 and TALAPRO-2
![AIOC 2023 FP64 Pediatric I topic DR MANISH BAKSI Comparison of risk factors and interventions for - YouTube AIOC 2023 FP64 Pediatric I topic DR MANISH BAKSI Comparison of risk factors and interventions for - YouTube](https://i.ytimg.com/vi/XxSdKIV6TRA/maxresdefault.jpg?sqp=-oaymwEmCIAKENAF8quKqQMa8AEB-AH-CYAC0AWKAgwIABABGEYgZShlMA8=&rs=AOn4CLAUOwG28RtD5BiOsXyujZ_j3fqKYw)